Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Long-Term Investments (2021 - 2025)

Ovid Therapeutics (OVID) has disclosed Long-Term Investments for 5 consecutive years, with $20.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Investments fell 1.03% year-over-year to $20.9 million, compared with a TTM value of $20.9 million through Sep 2025, down 1.03%, and an annual FY2024 reading of $21.0 million, up 18.99% over the prior year.
  • Long-Term Investments was $20.9 million for Q3 2025 at Ovid Therapeutics, roughly flat from $20.9 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $22.0 million in Q1 2024 and bottomed at $1.6 million in Q2 2021.
  • Average Long-Term Investments over 5 years is $12.5 million, with a median of $16.3 million recorded in 2023.
  • The sharpest move saw Long-Term Investments surged 639.07% in 2023, then fell 5.06% in 2025.
  • Year by year, Long-Term Investments stood at $1.6 million in 2021, then surged by 244.52% to $5.6 million in 2022, then soared by 213.49% to $17.6 million in 2023, then increased by 18.99% to $21.0 million in 2024, then fell by 0.31% to $20.9 million in 2025.
  • Business Quant data shows Long-Term Investments for OVID at $20.9 million in Q3 2025, $20.9 million in Q2 2025, and $20.9 million in Q1 2025.